Travere Therapeutics Appoints Ruth Williams-Brinkley to its Board of Directors
September 14 2021 - 4:30PM
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the
appointment of Ruth Williams-Brinkley to the Company’s Board of
Directors, effective immediately. Ms. Williams-Brinkley brings to
Travere more than 35 years of executive leadership in care delivery
and health plan operations.
“On behalf of the Board of Directors, I am pleased to welcome
Ruth to Travere,” said Gary Lyons, chairman of the Travere
Therapeutics Board of Directors. “She is a distinguished leader
with extensive experience in the delivery of care and is an
actively engaged and admired community leader. As we look to future
potential commercial launches from our pipeline, Ruth’s insights
will be instrumental in achieving our goal of enabling broad access
to our innovative therapies.”
Ms. Williams-Brinkley added: “This is an exciting time to join
the board of Travere as the organization advances towards
delivering new treatment options for people living with rare kidney
conditions, many of whom have been significantly underserved for
decades. I am proud to be joining a company that cares deeply about
the patients and caregivers it serves, and is a champion for
diversity, health equity and inclusion in the rare disease
community.”
Ms. Williams-Brinkley has served as President of the Kaiser
Foundation Health Plan for the Mid-Atlantic States since 2020,
overseeing all of Kaiser Permanente’s care delivery and health plan
operations in Washington, D.C., and suburban Maryland, Baltimore,
and Northern Virginia. Kaiser Permanente’s Mid-Atlantic States
region operates 34 medical offices and
has 789,030 members. She joined Kaiser Permanente in 2017
as President of Kaiser Foundation Health Plan and Hospitals of the
Northwest, in Portland, Oregon. Prior to her roles at Kaiser
Permanente, Ms. Williams-Brinkley served as CEO of KentuckyOne
Health, Kentucky’s largest integrated health system. KentuckyOne
was a division of CommonSpirit Health, one of the nation’s largest
nonprofit health systems. Before joining KentuckyOne Health, Ms.
Williams-Brinkley served as president and CEO of Carondelet Health
Network in Tucson, Arizona, and as president and CEO of Memorial
Healthcare System in Chattanooga, Tennessee.
Ms. Williams-Brinkley has repeatedly appeared on Modern
Healthcare’s “Top 25 Women in Healthcare” and “Top 25 Minority
Executives in Healthcare” lists, and she was named by Modern
Healthcare as one of “2020's 100 Most Influential People”. In
addition, Ms. Williams-Brinkley has been named one of Becker’s
Hospital Review’s “Most Admired CEOs”. Ms. Williams-Brinkley serves
on the not-for-profit Boards of DePaul University in Chicago,
Illinois and the Clinical Center Research Hospital Board of the
National Institutes of Health (NIH) in Washington, D.C., as well as
on the Board of Directors of University of Phoenix. She holds a
bachelor’s degree and a master’s of science degree in nursing from
DePaul University, and she has an honorary doctoral degree from
Spaulding University, Louisville, Ky. Ms. Williams-Brinkley is also
a Fellow of the American College of Healthcare Executives
(FACHE).
About Travere Therapeutics
At Travere Therapeutics, we are in rare for
life. We are a biopharmaceutical company that comes together every
day to help patients, families and caregivers of all backgrounds as
they navigate life with a rare disease. On this path, we know the
need for treatment options is urgent – that is why our global team
works with the rare disease community to identify, develop and
deliver life-changing therapies. In pursuit of this mission, we
continuously seek to understand the diverse perspectives of rare
patients and to courageously forge new paths to make a difference
in their lives and provide hope – today and tomorrow. For more
information, visit travere.com
Forward Looking Statements
This press release contains "forward-looking
statements" as that term is defined in the Private Securities
Litigation Reform Act of 1995. Without limiting the foregoing,
these statements are often identified by the words "may", "might",
"believes", "thinks", "anticipates", "plans", "expects", "intends"
or similar expressions. In addition, expressions of our strategies,
intentions or plans are also forward-looking statements. Such
forward-looking statements include, but are not limited to,
references to future potential commercial launches from the
Company’s pipeline and the Company’s ability to achieve its goal of
enabling broad access to its innovative therapies. Such
forward-looking statements are based on current expectations and
involve inherent risks and uncertainties, including factors that
could delay, divert or change any of them, and could cause actual
outcomes and results to differ materially from current
expectations. No forward-looking statement can be guaranteed. Among
the factors that could cause actual results to differ materially
from those indicated in the forward-looking statements are risks
and uncertainties associated with the regulatory review and
approval process, including the Subpart H accelerated approval
pathway in the United States and the conditional marketing
authorization (CMA) pathway in Europe. Specifically, the Company
faces the risk that the Phase 3 DUPLEX Study of sparsentan in FSGS
will not demonstrate that sparsentan is safe or effective or serve
as a basis for accelerated approval of sparsentan as planned; risk
that the Phase 3 PROTECT Study of sparsentan in IgAN will not
demonstrate that sparsentan is safe or effective or serve as the
basis for accelerated approval of sparsentan as planned; and risk
that sparsentan will not be approved for efficacy, safety,
regulatory or other reasons, and for each of the Company’s
programs, risk associated with enrollment of clinical trials for
rare diseases and risk that ongoing or planned clinical trials may
not succeed or may be delayed for safety, regulatory or other
reasons. The Company faces risk that it will be unable to raise
additional funding that may be required to complete development of
any or all of its product candidates; risk relating to the
Company's dependence on contractors for clinical drug supply and
commercial manufacturing; uncertainties relating to patent
protection and exclusivity periods and intellectual property rights
of third parties; risks associated with regulatory interactions;
and risks and uncertainties relating to competitive products,
including current and potential future generic competition with
certain of the Company’s products, and technological changes that
may limit demand for the Company's products. The Company faces
additional risks associated with the potential impacts the COVID-19
pandemic may have on its business, including, but not limited to
(i) the Company’s ability to continue its ongoing development
activities and clinical trials, (ii) the timing of such clinical
trials and the release of data from those trials, (iii) the
Company’s and its suppliers’ ability to successfully manufacture
its commercial products and product candidates, and (iv) the market
for and sales of its commercial products. You are cautioned not to
place undue reliance on these forward-looking statements as there
are important factors that could cause actual results to differ
materially from those in forward-looking statements, many of which
are beyond our control. The Company undertakes no obligation to
publicly update any forward-looking statement, whether as a result
of new information, future events, or otherwise. Investors are
referred to the full discussion of risks and uncertainties as
included in the Company's most recent Form 10-Q, Form 10-K and
other filings with the Securities and Exchange Commission.
Contact:
Chris Cline, CFASenior Vice President, Investor Relations &
Corporate Communications888-969-7879IR@travere.com
Travere Therapeutics (NASDAQ:TVTX)
Historical Stock Chart
From Apr 2024 to May 2024
Travere Therapeutics (NASDAQ:TVTX)
Historical Stock Chart
From May 2023 to May 2024